Related to this article

Image of Pancreas
Rasonque (daraxonrasib), the first approved drug to directly target RAS in pancreatic cancer, nearly doubled survival in a key trial. Two patients, a caregiver and the professionals who care for people like them explain what it means to live with the disease.